Is stabilization of disease a useful indicator for survival in second-line treatment of ovarian carcinoma pre-treated with Paclitaxel–Platinum?
| Autor: | B Gronlund, Svend Aage Engelholm, Claus Høgdall, H. H. Hansen, Ib Jarle Christensen |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Oncology
medicine.medical_specialty Paclitaxel medicine.medical_treatment Antineoplastic Agents Carboplatin Cohort Studies Ovarian carcinoma Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Aged Neoplasm Staging Retrospective Studies Ovarian Neoplasms Chemotherapy Proportional hazards model business.industry Palliative Care Hazard ratio Obstetrics and Gynecology Middle Aged Prognosis medicine.disease Surgery Female Topotecan Cisplatin Neoplasm Recurrence Local business Ovarian cancer Recurrent Ovarian Carcinoma Progressive disease medicine.drug |
| Zdroj: | Gynecologic Oncology. 94:409-415 |
| ISSN: | 0090-8258 |
| DOI: | 10.1016/j.ygyno.2004.05.005 |
| Popis: | Objective. Recurrent ovarian carcinoma is considered an incurable disease and second-line chemotherapy is administered for extension of survival and palliation. The impact of continued antineoplastic treatment in patients with stable disease without a demonstrable response is uncertain. The aim of this analysis was to assess the value of a stabilization of the tumor size in second-line chemotherapy as an indicator of survival. Methods. Retrospective, single-institution study of 487 consecutive patients with primary epithelial ovarian carcinoma. Inclusion criteria: (1) FIGO stage IC–IV epithelial ovarian carcinoma; (2) first-line chemotherapy with Paclitaxel and a Platinum-compound; (3) refractory, persistent, or recurrent disease diagnosed by imaging methods; and (4) intravenous second-line chemotherapy with single Topotecan or Paclitaxel–Carboplatin. Univariate and multivariate analyses of survival with the World Health Organization (WHO) tumor response parameter included as a time-dependent variable were performed. Results. The response rates were ( N = 100): complete response (CR) 27%, partial response (PR) 14%, stable disease (SD) 41% and progressive disease (PD) 18%. In a multivariate Cox regression analysis of survival, SD was found to be an independent prognostic factor for survival and the death hazard ratio was 0.37 (SD versus PD; 95% CI: 0.16–0.86; P = 0.02). There was no statistically significant difference in survival between patients with PR and SD ( P = 0.09). Conclusion. In second-line chemotherapy of ovarian cancer, patients demonstrating SD have a survival benefit compared to patients with PD measured by the WHO tumor response criteria. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect